I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| type I pneumocyte | 6 studies | 24% ± 5% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| type I pneumocyte | 6 studies | 24% ± 5% |
Insufficient scRNA-seq data for expression of IL17RE at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| pancreas | 99% | 826.26 | 326 / 328 | 95% | 22.43 | 169 / 178 |
| lung | 97% | 1043.97 | 560 / 578 | 93% | 14.62 | 1079 / 1155 |
| thymus | 99% | 794.80 | 644 / 653 | 91% | 11.50 | 553 / 605 |
| breast | 99% | 1103.54 | 456 / 459 | 86% | 15.47 | 959 / 1118 |
| intestine | 86% | 1630.25 | 828 / 966 | 98% | 32.95 | 517 / 527 |
| stomach | 85% | 1833.94 | 305 / 359 | 97% | 28.81 | 276 / 286 |
| bladder | 81% | 425.90 | 17 / 21 | 90% | 18.24 | 454 / 504 |
| prostate | 97% | 1115.97 | 238 / 245 | 71% | 6.67 | 358 / 502 |
| uterus | 75% | 377.64 | 127 / 170 | 84% | 11.77 | 386 / 459 |
| esophagus | 56% | 608.32 | 804 / 1445 | 97% | 15.85 | 177 / 183 |
| skin | 89% | 3706.18 | 1601 / 1809 | 38% | 3.22 | 177 / 472 |
| liver | 51% | 381.47 | 115 / 226 | 61% | 7.73 | 249 / 406 |
| kidney | 84% | 508.82 | 75 / 89 | 27% | 2.51 | 244 / 901 |
| ovary | 16% | 69.79 | 29 / 180 | 87% | 8.16 | 372 / 430 |
| ureter | 0% | 0 | 0 / 0 | 100% | 18.27 | 1 / 1 |
| blood vessel | 99% | 1291.09 | 1320 / 1335 | 0% | 0 | 0 / 0 |
| adipose | 99% | 1064.66 | 1187 / 1204 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 96% | 10.24 | 43 / 45 |
| adrenal gland | 26% | 84.15 | 67 / 258 | 43% | 3.80 | 98 / 230 |
| brain | 37% | 314.19 | 979 / 2642 | 12% | 0.50 | 82 / 705 |
| spleen | 36% | 138.04 | 86 / 241 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 13% | 0.53 | 10 / 80 |
| heart | 12% | 43.20 | 100 / 861 | 0% | 0 | 0 / 0 |
| muscle | 1% | 4.13 | 9 / 803 | 0% | 0 | 0 / 0 |
| peripheral blood | 0% | 0.73 | 2 / 929 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0019221 | Biological process | cytokine-mediated signaling pathway |
| GO_0006954 | Biological process | inflammatory response |
| GO_0005576 | Cellular component | extracellular region |
| GO_0005886 | Cellular component | plasma membrane |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0030368 | Molecular function | interleukin-17 receptor activity |
| GO_0005515 | Molecular function | protein binding |
| Gene name | IL17RE |
| Protein name | Interleukin 17 receptor E Alternative protein IL17RE Interleukin-17 receptor E (IL-17 receptor E) (IL-17RE) |
| Synonyms | UNQ3056/PRO9877 hCG_1759140 |
| Description | FUNCTION: Specific functional receptor for IL17C. May be signaling through the NF-kappa-B and MAPK pathways. May require TRAF3IP2 /ACT1 for signaling. May be a crucial regulator in innate immunity to bacterial pathogens. Isoform 2 and isoform 4 may be either cytoplasmic inactive or dominant active forms. Isoform 3 and isoform 5 may act as soluble decoy receptors. . |
| Accessions | Q8NFR9 ENST00000454190.6 [Q8NFR9-3] F8WB54 ENST00000383815.7 J3KQN7 ENST00000421412.5 ENST00000434065.5 ENST00000454992.1 ENST00000383814.8 [Q8NFR9-1] L8E985 F8WCU7 A6NL85 L0R6I5 ENST00000444427.5 C9J1R2 |
